Key points are not available for this paper at this time.
CAC may have the potential to help match statin therapy to absolute CVD risk. Across the spectrum of dyslipidemia, event rates similar to secondary prevention populations were observed for patients with CAC ≥ 100.
Martin et al. (2013) studied this question.